Core Viewpoint - The announcement details the provision of guarantees by the company for its wholly-owned and controlling subsidiaries, aimed at supporting their financing needs and promoting business development [1][5]. Summary by Sections Guarantee Overview - The company has provided a guarantee of RMB 6.8 million for its wholly-owned subsidiary, Zhejiang Tongjuntang Traditional Chinese Medicine Co., Ltd., and a guarantee of RMB 4 million for its controlling subsidiary, New Leading (Chongqing) Pharmaceutical Technology Co., Ltd. [1] - The total actual guarantee balance for Zhejiang Tongjuntang is RMB 145 million (including this guarantee), and for Chongqing New Leading, it is RMB 13.57 million (including this guarantee) [1]. Approval Process - The company held board meetings on April 7, 2025, and April 29, 2025, to approve the provision of guarantees for the fiscal year 2025 [2]. - The company adjusted the unused guarantee quota of RMB 40 million from its subsidiary, Zhejiang Tongjuntang, to another subsidiary, Tongjuntang [2]. Financial Status of Guaranteed Entities - Zhejiang Tongjuntang Traditional Chinese Medicine Co., Ltd. has total assets of RMB 492.19 million and total liabilities of RMB 293.63 million, with a net profit of RMB 55.30 million [4]. - New Leading (Chongqing) Pharmaceutical Technology Co., Ltd. has total assets of RMB 25.75 million and total liabilities of RMB 11.99 million, with a net asset value of RMB 13.76 million [4]. Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to meet the operational and financing needs of the subsidiaries, aligning with the company's development strategy [5]. - The financial condition of the guaranteed entities is stable, and the overall risk is controllable, ensuring no significant impact on the company's daily operations [5]. Board Opinion - The board believes that the guarantees will enhance financing efficiency, reduce costs, and support sustainable business development, considering the subsidiaries' financial stability and creditworthiness [5]. External Guarantee Status - As of the announcement date, the company has no overdue guarantees and maintains a total external guarantee balance without any overdue items [6].

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-031 河南太龙药业股份有限公司 关于拟申请注册发行超短期融资券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日召开第九届董事会第三十二次会议，审议通过了《关于拟申请 注册发行超短期融资券的议案》。为拓宽融资渠道，增加债务融资的 多样性与灵活性，优化融资成本，根据《公司法》《银行间债券市场 非金融企业债务融资工具管理办法》等相关规定，并结合公司实际情 况，公司拟向中国银行间市场交易商协会申请注册发行总额不超过 （含）人民币 8 亿元的超短期融资券，具体情况如下： 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-031 一、本次超短期融资券注册发行方案主要内容 （一）注册和发行规模：拟注册发行规模不超过（含）人民币 8 亿元，具体发行规模将以公司在中国银行间市场交易商协会注册的金 额为准。 （二）发行期限：单期发行期限不超过 270 天（含）。 （三）发行方式 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-029 河南太龙药业股份有限公司 被担保人名称：公司下属全资子公司浙江桐君堂中药饮片有限 公司（以下简称"中药饮片公司"）、下属控股子公司新领先（重庆） 医药科技有限公司（以下简称"重庆新领先"）。 本次担保金额及已实际为其提供的担保余额：本次为中药饮片 公司提供的担保金额为 680 万元，为重庆新领先提供的担保金额为 400 万元。截至本公告日，河南太龙药业股份有限公司（以下简称"公 司"）及下属子公司已实际为中药饮片公司提供的担保余额为 14,500 万元(含本次)，已实际为重庆新领先提供的担保余额为 1,357.05 万 元(含本次)。 本次担保是否有反担保：否 对外担保逾期的累计数量：无 一、担保情况概述 （一）基本情况 1、近日，公司全资子公司桐君堂药业有限公司（以下简称"桐 君堂"）与杭州银行股份有限公司桐庐支行（以下简称"杭州银行桐 关于为下属全资及控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ...

证券代码：600222 证券简称：太龙药业 公告编号：2025-032 河南太龙药业股份有限公司 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 17 日 至2025 年 7 月 17 日 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 17 日 14 点 30 分 召开地点：郑州市高新技术产业开发区金梭路 8 号公司一楼会议室 股东大会召开日期：2025年7月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-030 河南太龙药业股份有限公司 第九届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 河南太龙药业股份有限公司（以下简称"公司"）第九届董事会 第三十二次会议于 2025 年 7 月 1 日在公司一楼会议室以现场结合通 讯的方式召开。会议通知已于 2025 年 6 月 26 日送达各位董事。本次 会议应出席董事 9 人，实际出席董事 9 人，其中副董事长李景亮先生、 独立董事方亮先生、独立董事刘玉敏女士以通讯方式出席。会议由董 事长尹辉先生召集并主持，监事列席了会议。会议的召集、召开及表 决程序符合有关法律、法规和《公司章程》的规定，所作决议合法有 效。 二、董事会会议审议情况 （一）审议通过《关于拟申请注册发行超短期融资券的议案》 本议案尚需提交公司股东大会审议。 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-030 （二）审议通过《关于召开 2025 年第二次临时股东大会的议案》 ...

Core Viewpoint - The company plans to issue a super short-term financing bond totaling no more than 800 million yuan to replace bank loans and supplement working capital [1] Group 1 - The board of directors has approved the application to the China Interbank Market Dealers Association for the bond issuance [1] - The bond will have a maturity of no more than 270 days [1] - The issuance is subject to approval by the shareholders' meeting and the China Interbank Market Dealers Association [1]

Investment Rating - The report assigns an "Accumulate" rating for the company [4] Core Viewpoints - The company benefits from the revival of traditional Chinese medicine, with stable core business and a strong moat for its "Shuanghuanglian" product series, which is expected to benefit from differentiation, segmentation, and upgrading trends [3] - The new controlling shareholder has strong background and capabilities, which will enhance resource matching, management models, and development strategies, promoting long-term and sustainable growth [3] Financial Performance Summary - Revenue is projected to reach CNY 2,070 million in 2023, with a year-on-year growth rate of 5.6%, followed by a decline of 6.2% in 2024, and then a recovery with growth rates of 9.8%, 10.1%, and 10.0% in the subsequent years [1] - Net profit attributable to shareholders is expected to grow significantly from CNY 44 million in 2023 to CNY 116 million by 2027, reflecting a year-on-year growth rate of 160.3% in 2023 and steady growth thereafter [1] - The company's return on equity (ROE) is projected to improve from 2.8% in 2023 to 6.4% by 2027 [1] Business Segments Summary - The company has a diversified business layout, including drug manufacturing and research services, with a focus on traditional Chinese medicine [12] - The "Shuanghuanglian" oral liquid is a leading product, capturing over 30% market share in 2023, with sales exceeding CNY 700 million [2] - The company’s CRO (Contract Research Organization) business is expected to experience growth due to favorable regulatory changes and increased demand for drug research services [2][3] Market Position and Competitive Landscape - The company ranks third in the market for cold medicine in public medical institutions, with a significant presence in the hospital sector [38] - The recent national centralized procurement is expected to enhance the company's market position, as the selected prices for its products remain stable, indicating limited impact on pricing [2][59]

Summary of Key Points Core Viewpoint - The company has provided a guarantee of 20 million RMB for its subsidiary, Beijing New Leading Pharmaceutical Technology Development Co., Ltd., to support its financing needs, which is part of a broader strategy to enhance operational efficiency and financial stability [2][11]. Group 1: Guarantee Details - The guarantee amount for the subsidiary is 20 million RMB, with a total guarantee balance of 108.17 million RMB as of the announcement date [2][14]. - The guarantee is provided without any counter-guarantee and there are no overdue guarantees [3][14]. - The guarantee is part of a maximum guarantee limit of 430 million RMB approved for the fiscal year 2025 [4][14]. Group 2: Subsidiary Information - Beijing New Leading has a registered capital of 91.55 million RMB and is primarily engaged in medical research and technology services [6][8]. - The company holds an 87.38% stake in the subsidiary, indicating significant control over its operations [8][12]. Group 3: Guarantee Agreement - The guarantee agreement with Beijing Bank Zhongguancun Branch includes a maximum principal amount of 20 million RMB and covers all debts, including principal, interest, penalties, and other related costs [9][11]. - The guarantee period extends for three years from the maturity of the secured debt [10]. Group 4: Board's Opinion - The board of directors believes that the guarantee is necessary for the subsidiary's operational growth and aligns with the company's strategic goals, ensuring that the subsidiary can meet its financial obligations [13].